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Abstract: Treatment to target fasting blood glucose (FBG), postprandial glucose (PPG) and HbA1c 
are essential in the management of type 2 diabetes to reduce the risk of vascular complications. 
Early combination therapy with oral agents is increasingly being seen as important to achieve 
this. Repaglinide, a rapid-acting insulin secretagogue, targets PPG, and metformin, an insulin 
sensitizer, targets FBG. Because of their complementary modes of action these therapies are 
frequently given as combination therapy in separate tablets. To overcome the issues with adher-
ence to multiple tablets, repaglinide and metformin are now available in a fixed-dose combination 
(FDC). Repaglinide/metformin FDC is bioequivalent to each tablet given separately, suggesting 
that the efficacy and safety profile is similar. There is no effect of food on repaglinide when 
in the FDC. Repaglinide/metformin FDC is as effective in reducing HbA1c and FBG whether 
given twice or three times daily, with a similar safety profile. Repaglinide/metformin FDC 
twice daily is as effective in reducing HbA1c and FBG as rosiglitazone/metformin FDC with a 
similar safety profile, but unlike the rosiglitazone/metformin FDC, repaglinide/metformin FDC 
improves the lipid profile. Repaglinide/metformin FDC represents a new option in the pursuit 
of achieving glucose targets and reducing vascular risk in type 2 diabetes, with the advantage 
of improving adherence.
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Introduction
Management issues in diabetes
Type 2 diabetes is characterized by defects both in insulin secretion from the beta cells 
and in insulin sensitivity, leading to hyperglycemia and the resulting increased risk of 
microvascular and macrovascular complications. To reduce the risk of these vascular 
complications, intensive treatment to target fasting blood glucose (FBG) concentra-
tions, postprandial glucose (PPG) concentrations and glycosylated hemoglobin (HbA1c) 
levels is a key goal in the management of patients with type 2 diabetes.
The response of the beta cell after a meal in people with type 2 diabetes is in two 
phases: the first phase 0 to 10 minutes after a meal, followed by a steady and more 
prolonged second phase. The loss of the first phase is a key determinant of postprandial 
hyperglycemia and is characteristic both of impaired glucose tolerance and type 2 
diabetes.1 While HbA1c is the accepted measure of glucose control over time, Monnier 
and colleagues have shown that the relative contribution of postprandial hyperglycemia 
to overall hyperglycemia varies with HbA1c levels.2 Postprandial hyperglycemia is 
the main contributor to overall daily hyperglycemia in people with mild or moderate Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2009:2 102
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hyperglycemia, whereas fasting hyperglycemia is the 
main contributor in people whose diabetes is more poorly 
controlled. Specifically, the role of fasting hyperglycemia 
becomes most important when HbA1c rises above 8.4%; 
as control of hyperglycemia improves with treatment, the 
role of PPG therefore becomes more important.2 Given the 
importance of both PPG and FBG to overall hyperglycemia it 
is rational to target both PPG and FBG concentrations when 
treating hyperglycemia in type 2 diabetes.
Evidence for the effects of intensive treatment on vascular 
outcomes comes from the United Kingdom Prospective 
Diabetes Study (UKPDS); initial results from this study 
showed that intensive treatment resulted in a decreased risk of 
microvascular, but not macrovascular complications.3 How-
ever, during the 10 years of follow up of the UKPDS there 
were continued risk reductions for microvascular events in the 
intensively treated group compared with the conventionally 
treated group and the risk reductions for myocardial infarction 
became significantly different between groups (despite a loss 
of glycemic differences between groups).4 Furthermore, a 
prospective observational analysis of the UKPDS showed that 
each 1% reduction in mean HbA1c was associated with risk 
reductions of 21% for any endpoint related to diabetes, 21% 
for deaths related to diabetes, 14% for myocardial infarction 
and 37% for microvascular complications.5 However, there are 
some recent data that contradict the UKPDS data. The Action 
to Control Cardiovascular Risk in Diabetes (ACCORD) trial 
was stopped early because of an increased death rate in the 
intensive control group (HbA1c target of 6.0%) compared 
with the standard therapy group (HbA1c target of 7.0% to 
7.9%).6 While no apparent increase in mortality was found 
in the Action in Diabetes and Vascular Disease: Preterax 
and Diamicron Modified Release Controlled Evaluation 
(ADVANCE) trial, intensive therapy (mean HbA1c of 6.5% 
over 5 years) did not significantly reduce the risk of major 
macrovascular events compared with standard therapy (mean 
HbA1c of 7.3% over 5 years), but nephropathy was signifi-
cantly reduced in the intensive treatment group.7 Similarly, 
the Veteran Affairs Diabetes Trial (VADT) detected no 
difference in macrovascular or microvascular complication 
rates between patients treated intensively (median HbA1c of 
6.9% over 5.6 years) or those receiving standard treatment 
(median HbA1c of 8.4% over 5.6 years).8
Despite the recent data from ACCORD, ADVANCE 
and VADT, a joint statement from the American College 
of Cardiology, American Diabetes Association (ADA) and 
American Heart Association reassures clinicians that, because 
of the other significant evidence for the benefits of reducing 
HbA1c, clinicians should continue to reduce HbA1c to targets 
of below 7.0%, except for certain specific situations.9
Another observation from the UKPDS was that treatment 
with metformin decreases the risk of any diabetes-related 
endpoints, diabetes-related mortality and all-cause mortality 
in overweight people with type 2 diabetes compared with 
conventional treatment (primarily diet), sulfonylureas or 
insulin.10 These findings were consistent throughout 10 years 
of follow up.4 UKPDS also showed that people treated with 
sulphonlyureas, who had metformin added early in the 
course of their treatment, had an increased risk of diabetes-
related death, compared with sulfonylureas alone.10 Rao 
and colleagues carried out a meta-analysis of this and other 
studies (some with similar findings and others with conflict-
ing findings) and found that the combination of sulfonylureas 
and metformin significantly increased the relative risk of 
the composite endpoint of cardiovascular hospitalization or 
mortality, but that this combination had no effect on either 
CVD mortality or all-cause mortality alone.11 The authors sug-
gested that the increased risk may stem from: the association of 
sulfonylureas with weight gain; the potential for sulfonylureas 
to cause hypoglycemia and the potential for the addition of 
metformin to impair recovery from hypoglycemia (which may 
increase ischemia and arrhythmias); or the fact that patients 
who need this combination may have a more aggressive form 
of the disease.11 Nevertheless, because intensive glucose 
control with metformin decreases the risk of diabetes-related 
endpoints in overweight people with diabetes, and is associated 
with less weight gain and fewer hypoglycemic attacks than 
insulin and sulfonylureas, metformin has become a first-line 
pharmacological therapy for people with type 2 diabetes.
Combination therapy in type 2 diabetes
Traditionally, the first step in the management of people with 
type 2 diabetes was to provide advice on lifestyle changes to 
reduce hyperglycemia, and when these ceased to be effective 
the recommended approach to drug therapy was stepwise: 
starting with oral monotherapy, progressing to combination 
dual and triple therapy, and eventually to insulin. However, in 
acknowledgment of the limited long-term success of lifestyle 
changes alone and the need for intensive therapy, a recent 
consensus statement from the European Association for the 
Study of Diabetes (EASD) and the ADA recommended that 
metformin should be introduced at the same time as lifestyle 
measures.12
Earlier treatment with combination therapies that target 
both FBG and PPG is also increasingly being adopted as 
an approach, because monotherapy frequently fails. ADA/Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2009:2 103
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EASD recommend that when glucose concentrations are 
high (HbA1c  8.5%), classes of drugs with greater and more 
rapid glucose-lowering effects are used, or that combination 
therapy is initiated early.12
Studies suggest that fixed-dose combinations (FDC) 
may have a positive effect on concordance and glycemic 
control. In one observational study there were no significant 
differences in adherence rates among newly treated patients 
receiving monotherapy, combination therapy, or FDC therapy; 
however, in patients who had previously been treated with 
glibenclamide or metformin and who required the addition of a 
second agent, adherence rates were significantly lower in those 
who added in a second agent than in those who switched to 
FDC therapy. Patients already receiving combination therapy 
who were switched to FDC therapy also had a significant 
improvement in adherence after the switch.13 A retrospective 
study of a FDC of metformin and glibenclamide showed that 
patients with type 2 diabetes receiving the FDC had a signifi-
cantly greater reduction in HbA1c than those on glibenclamide 
co-administered with metformin, especially when baseline 
HbA1c was 8%. While patients were more concordant with 
the FDC, regression analysis indicated that concordance was 
not a significant predictor of change in HbA1c.14
Repaglinide, a rapid-acting insulin secretagogue, and 
metformin, an insulin sensitizer, are now available in a FDC 
(repaglinide/metformin FDC); the evidence supporting the 
use of this combination in the management of type 2 diabetes 
is reviewed here.
Repaglinide and metformin 
combination therapy
repaglinide
In animal studies, a mechanism of action for repaglinide has 
been postulated. It appears that repaglinide stimulates insulin 
secretion, in the presence of glucose, by binding to sites on 
ATP-dependent potassium channels in the beta cell, resulting 
in closure of the potassium channels, beta cell depolarization, 
opening of calcium channels, increased calcium ion flux 
and upregulation of insulin secretion (Figure 1).15,16 While 
potassium channels are also the target for sulfonylureas, repa-
glinide is structurally distinct from the sulfonylureas but with 
some chemical resemblance to the nonsulfonylurea moiety of 
the molecule of the sulfonylurea glibenclamide. Repaglinide 
causes insulin secretion only when glucose is present, which 
reduces the chance of insulin secretion when blood glucose 
concentrations are very low.17 Sulphonylureas, on the other 
hand, can cause insulin secretion even when there is no 
glucose present, increasing the chance of hypoglycemia.
Peak plasma levels of repaglinide occur within 1 hour of 
oral intake and, when taken with a meal, repaglinide results 
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Figure 1 Mode of action of repaglinide.   Adapted with permission from wolffenbuttel BH. repaglinide – a new compound for the treatment of patients with type 2 diabetes. 
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in an early first phase rise in insulin levels, which specifically 
targets postprandial hyperglycemia.16 Repaglinide is rapidly 
eliminated, with a half-life of approximately 1 hour after 
either single, or multiple oral doses in people with, and 
without, type 2 diabetes.16 Because repaglinide is rapidly 
and completely absorbed from the gastrointestinal tract it 
is used in a meal-related dosing regimen, which reflects 
the physiological response to food.16 Repaglinide promotes 
insulin secretion only in the presence of glucose, which may 
reduce the likelihood of insulin secretion when blood glucose 
levels are very low – in theory this may therefore reduce 
the incidence of hypoglycemia.17 It has been shown that 
people who are taking repaglinide are less likely to develop 
symptoms of hypoglycemia if they miss or postpone a meal 
in comparison with those taking sulfonylureas.18
Repaglinide is at least as effective as sulfonylureas in 
reducing HbA1c and FBG,16,19,20 with reductions in HbA1c of 
up to 2.3% after 10 weeks’ treatment in patients who have not 
previously been treated with oral agents.21 Repaglinide also 
decreases PPG to at least the same extent as sulfonylureas.20 
The reduction in HbA1c is significantly greater with repa-
glinide compared with the meglitinide nateglinide.22,23
The risk of weight gain with repaglinide is similar to 
the risk with sulfonylureas;16,19,20 repaglinide may cause 
less weight gain in people not previously treated with oral 
agents.19 Repaglinide has also been shown to improve homeo-
stasis model assessment of insulin resistance (HOMA-IR) 
and beta cell function indexes measured by HOMA-beta.22
Metformin
Metformin is an insulin sensitizer that acts by inhibiting 
hepatic glucose output, increasing peripheral glucose uptake 
and utilization, and thus lowering FBG concentrations.24 In 
clinical trials, metformin has been shown to reduce HbA1c and 
FBG significantly more than placebo and to the same extent 
as sulfonylureas,25 and to lower PPG concentrations.26
Although metformin is generally well tolerated, some 
patients report gastrointestinal adverse effects, which can 
be reduced by starting treatment at a low dose and slowly 
titrating upwards. Treatment with metformin is not associated 
with hypoglycemia, and results in weight stability or moder-
ate weight loss,25,27 which is of particular benefit in people 
with type 2 diabetes who are often overweight.
rationale for combination of repaglinide 
with metformin
As discussed above, a rational approach to the management of 
type 2 diabetes is to target both FBG and PPG concentrations. 
Metformin, by virtue of its action of decreasing liver glucose 
production and increasing glucose uptake in peripheral 
tissues, reduces FBG; repaglinide, by targeting the ATP-
dependent calcium channel in the beta cells, increases insulin 
production (Figure 2). The two therapeutic agents therefore 
have a complementary effect. Furthermore, repaglinide in 
combination with metformin has been shown to significantly 
enhance the insulin secretion index (a measure of the glucose 
clearance rate per unit serum insulin concentration), sug-
gesting a synergistic effect of the two molecules on insulin 
sensitivity.28
Existing clinical evidence supports the use of these 
two agents in combination therapy. The combination of 
repaglinide and metformin taken as separate tablets has 
already been established as providing greater reductions in 
HbA1c and FPG values compared with either tablet alone.29 
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Figure 2 Complementary mode of actions of repaglinide and metformin. raskin P. Oral combination therapy: repaglinide plus metformin for treatment of type 2 diabetes. 
Diabetes Obes Metab. 2008;10(12):1167–1177.43 Copyright © 2008 John wiley & Sons. reproduced with permission of Blackwell Publishing Ltd.Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2009:2 105
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A recent re-analysis of data from this study showed that 
more than 56% of patients receiving combination therapy 
achieved a target HbA1c of 7% compared with 19% in both 
monotherapy groups.30 In a second study investigating HbA1c 
targets with combination therapy in patients with previously 
poor glycemic control, a higher proportion of those given 
repaglinide plus metformin reached the target HbA1c of 7% 
than those given repaglinide alone (71% vs 48%).31
In a study comparing the combination of repaglinide 
and metformin, with the combination of nateglinide and 
metformin, the repaglinide combination resulted in greater 
reductions in HbA1c (1.28% for repaglinide; 0.67% for 
nateglinide) and FBG (39 mmol/L for repaglinide; 21 mmol/L 
for nateglinide) than the nateglinide combination.32
These data have led to the widespread co-administration 
of repaglinide and metformin as separate formulations to 
patients with type 2 diabetes. The combination of the two 
treatments may allow patients who experience side effects 
with metformin to reduce the dose of metformin without a 
loss of glycemic control. However, a single combination 
therapy tablet would offer increased patient convenience and 
the subsequent potential for increased therapy adherence. 
A fixed-dose, single tablet combination of these two drugs 
has now been assessed in clinical trials, and the pharmaco-
kinetic, efficacy and safety data of this FDC are the focus of 
the remainder of this review paper.
Pharmacokinetics of repaglinide/
metformin FDC
The pharmacokinetics of repaglinide/metformin FDC have 
been investigated in two studies – one to compare the 
bioequivalence of the FDC formulation with that of each 
component-drug administered individually, and the second 
to compare the pharmacokinetics of the FDC in the fed and 
fasted state.
The bioequivalence study was a randomized, single-
blind, three-period crossover study.33 Ninety-three healthy 
volunteers were randomized to receive either an FDC tablet 
of repaglinide/metformin 2 mg/500 mg, an FDC tablet of 
repaglinide/metformin 1 mg/500 mg, or repaglinide 2 mg 
and metformin 500 mg co-administered as separate formula-
tions, before a high-fat meal, in one of six possible treatment 
sequences. Both repaglinide and metformin in the combina-
tion tablet were bioequivalent to the individual tablets of 
repaglinide 2 mg and metformin 500 mg as measured by 
AUC and Cmax. The FDC tablet of repaglinide/metformin 
2 mg/500 mg was dose proportional to the FDC tablet of 
repaglinide/metformin 1 mg/500 mg for AUC and Cmax. 
There were no unexpected safety concerns in those treated 
with repaglinide/metformin FDC tablet therapy, and there 
were no withdrawals due to adverse events.33
The finding that both therapies in the FDC were bio-
equivalent to each therapy administered separately suggests 
that the FDC would have a similar safety and efficacy profile 
to repaglinide and metformin administered separately.
The study to compare the pharmacokinetics of repa-
glinide/metformin FDC under fasting and fed conditions was 
a randomized, single-blind, four-period, crossover study.34 
Sixty-two healthy volunteers were randomized to one of 
four possible sequences and received a single dose of study 
medication per treatment period, either: an FDC tablet of 
repaglinide/metformin 2 mg/850 mg under fasted and fed 
conditions (high-fat breakfast); repaglinide 2 mg (fasted 
conditions); or metformin 850 mg (fasted conditions). In the 
fasted state the FDC was bioequivalent to 850 mg metformin 
and it was bioequivalent to repaglinide 2 mg measured by 
area under the curve (AUC) but not Cmax. In people who had 
eaten a meal the AUC for metformin with the FDC was 15% 
to 24% lower and Cmax was 17% to 28% lower than under fast-
ing conditions. For repaglinide in the FDC, Cmax was 15% to 
44% higher in people who had eaten a meal than under fasting 
conditions but the AUC showed bioequivalence between the 
two states.34 The results of this study suggest that there was 
no food effect on total repaglinide exposure in the FDC.
Efficacy and safety of repaglinide/
metformin FDC
Comparison of repaglinide/metformin 
FDC twice daily and three times daily
The efficacy and safety of repaglinide/metformin FDC was 
investigated in a three-arm, 26-week, open label trial.35–38 
Patients with type 2 diabetes, diagnosed for at least 3 months 
with FBG  260 mg/dL, previously treated with either 
monotherapy or dual therapy, were randomized to receive 
either repaglinide/metformin FDC twice daily, repaglinide/
metformin FDC three times daily or rosiglitazone/metformin 
FDC twice daily. HbA1c ranged from 7.5% to 11% for those 
previously on monotherapy and from 7% to 10% for those 
previously on dual therapy.
One of the primary objectives of the trial was to compare 
the efficacy, measured by reduction in HbA1c, of repaglinide/
metformin FDC twice daily with repaglinide/metformin 
FDC three times daily.35 Repaglinide/metformin FDC 
twice daily was found to be non-inferior to repaglinide/
metformin FDC three times daily in terms of reduction in Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2009:2 106
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HbA1c (Table 1). No significant difference was seen in the 
number of patients reaching target HbA1c of either 6.5% or 
7.0% (Figure 3).
The investigators also carried out a subset analysis, 
comparing those who had previously been treated with oral 
monotherapy with those on dual therapy.37 The reduction 
in HbA1c was greatest in patients who had previously been 
on monotherapy, but the difference was not significant, 
most likely because of less advanced disease in patients on 
monotherapy, who therefore probably had more residual 
beta cell function than those on dual therapy. More patients 
who had been on monotherapy achieved HbA1c targets, and 
significantly more patients in the three times daily group 
previously on monotherapy reached the target of 7.0% than 
those previously on monotherapy in the twice daily group 
(Figure 3). FBG was reduced in both treatment groups and the 
reduction in FBG was greater in patients who were previously 
on monotherapy in both treatment groups (Table 1). Most 
lipid parameters decreased slightly from baseline but there 
were no significant differences between treatment groups.
Patients on the twice daily regimen gained weight 
(0.48 kg), whereas those on the three times daily regimen lost 
weight (0.33 kg; p = 0.033), but the difference was small and 
not clinically relevant.35 When this was analyzed by previous 
therapy, patients who had previously been on monotherapy 
had modest weight gain, whereas those previously on dual 
therapy lost weight in both treatment groups.
The types and frequencies of adverse events were compa-
rable between groups. No major hypoglycemic episodes were 
reported and rates of minor hypoglycemia were similar. In 
the subset analysis, minor hypoglycemia rates were slightly 
higher in patients who were previously on monotherapy, 
compared with those on dual therapy.37
Overall, the safety and efficacy of the twice daily regimen 
is similar to the three times daily regimen repaglinide/
metformin FDC, whether patients were previously on mono-
therapy or dual therapy.
Comparison of repaglinide/metformin 
FDC with rosiglitazone/metformin FDC
Another primary objective of the three-arm, 26-week, 
open-label trial described above was to compare the glycemic 
control measured by reduction in HbA1c in patients treated 
with repaglinide/metformin FDC twice daily with rosiglitazone/
metformin FDC twice daily. Patients on repaglinide/metformin 
FDC twice daily had a reduction in HbA1c of  0.95%; those on 
rosiglitazone/metformin FDC twice daily had a reduction of 
0.98% (Table 2).36 The difference was not significant, leading 
to the conclusion that treatment with repaglinide/metformin 
FDC twice daily was non-inferior to rosiglitazone/metformin 
FDC twice daily.
In the subset analysis38 the reduction in HbA1c was greater 
in patients who had previously been on monotherapy than 
those who had been on dual therapy, but differences were 
non-significant (Table 2). Again, this is likely to be a result 
of greater residual beta cell function in patients who were 
previously on monotherapy.
There were no significant differences between treatment 
groups in the numbers of patients achieving target HbA1c of 
either 6.5% or 7.0% (Figure 4).
The reduction in FBG was significantly higher in patients 
treated with rosiglitazone/metformin FDC twice daily, 
Table 1 Changes in HbA1c, FBG, weight and rate of minor hypoglycemia in patients on repaglinide/metformin FDC twice daily (monotherapy 
and dual therapy) and repaglinide/metformin FDC three times daily (monotherapy and dual therapy)
Variable Repaglinide/metformin FDC 
twice daily
Repaglinide/metformin FDC three 
times daily
All (n = 187) MT (n = 98) DT (n = 89) All (n = 187) MT (n = 91) DT (n = 96)
Duration of type 2 diabetes 6.6 8.3 5.6 8.9
Baseline HbA1c 8.4 8.7 8.2 8.3 8.4 8.2
∆HbA1c –0.95 –1.27 –0.62 –1.08 –1.48 –0.69
% HbA1c  6.5% 25.4 29.0 21.4 25.8 35.3 17.2
% HbA1c  7.0% 42.9 44.1** 41.7 48.9 58.8 39.8
∆FBG –18.4 –24.6** –11.9 –22.9 –36.3 –10.3
∆weight 0.48* 1.7 –0.9 –0.33 0.7 –1.2
Minor hypoglycemia (events/patient year) 3.79 4.8 2.6 4.46 5.3 3.8
*p  0.05 compared with three times daily dosing; **p  0.05 compared with three times daily dosing patients on MT.
Abbreviations: MT, monotherapy; DT, dual therapy; ∆, end of study change from baseline.Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2009:2 107
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compared with those on repaglinide/metformin FDC. When 
this was analyzed according to previous mono or dual therapy, 
the reduction in FBG was significantly greater in patients on 
rosiglitazone/metformin FDC twice daily who had previously 
been on monotherapy compared with those on repaglinide/
metformin FDC, but there was no significant difference in 
those who had previously been on dual therapy.36,38
Lipid  measurements  were  reduced  in  patients 
on repaglinide/metformin FDC twice daily, while patients 
on rosiglitazone/metformin FDC had increases in lipid 
measurements; the differences between treatment groups 
were significant for total cholesterol, low-density lipoprotein 
and non-high-density lipoprotein, but not for triglycerides. 
The subset analysis reflected these results. These results are 
reasonably consistent with previous studies. Metformin has 
been shown to reduce triglycerides and free fatty acids to the 
same extent as repaglinide, but to reduce total cholesterol, 
low-density lipoprotein and non-high-density lipoprotein to 
a greater extent.39 In a study comparing the lipid responses 
of several oral hypogylcemic agents, including metformin, 
rosiglitazone and pioglitazone, metformin reduced total 
cholesterol at high doses, but the results for other lipid param-
eters were inconclusive.40 Pioglitazone had a more favorable 
effect overall on the lipid profile than rosiglitazone, a finding 
that has been confirmed in other clinical trials.41
There were no significant differences in change in weight 
between treatment groups or in the subset analysis. In the com-
parison of repaglinide/metformin FDC and rosiglitazone/met-
formin FDC, the rate of minor hypoglycemia was significantly 
higher in the repaglinide/metformin FDC group. However, 
more than 50% of these minor hypoglycemic episodes were 
reported by seven people. The rate of minor hypoglycemia was 
slightly higher in those previously on monotherapy compared 
with those on dual therapy in both treatment groups.36,38
The repaglinide/metformin FDC provides similar efficacy, 
including reductions in HbA1c, to rosiglitazone/metformin 
FDC, but there was a significant difference in changes in 
lipid profiles between groups; in those taking rosiglitazone, 
lipid profiles worsened but in those taking repaglinide, lipid 
profiles improved.
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Figure 3 Percentage of patients treated with repaglinide/metformin FDC twice 
daily and three times daily achieving HbA1c targets of 6.5% and 7.0%. *p  0.05 
compared with three times daily dosing patients on previous MT.35,37 
Abbreviations: MT, previous OAD monotherapy; DT, previous OAD dual therapy.
Table 2 Changes in HbA1c, FPG, weight and rate of minor hypoglycemia in patients on repaglinide/metformin FDC twice daily (monotherapy 
and dual therapy) and rosiglitazone/metformin FDC twice daily (monotherapy and dual therapy)
Variable Repaglinide/metformin FDC twice daily Rosiglitazone/metformin FDC twice daily
All (n = 187) MT (n = 98) DT (n = 89) All (n = 187) MT (n = 97) DT (n = 90)
Baseline HbA1c 8.4 8.7 8.2 8.4 8.7 8.2
∆HbA1c –0.95 –1.27 –0.62 –0.98 –1.49 –0.46
% HbA1c  6.5% 25.4 29.0 21.4 25.3 34.8 15.3
% HbA1c  7.0% 42.9 44.1 41.7 48.9 58.4 38.8
∆FBG –18.4* –24.6* –11.9 –35.6 –49.1 –21.8
∆weight 0.48 1.7 –0.9 0.31 1.2 -0.6
Lipids
TC –1.3* –1.7* –1.0** 18.3 20.4 15.7
LDL –2.6* –2.3* –3.3** 9.6 10.6 8.3
HDL –0.2* –0.3* 0.1** 4.5 3.2 5.8
TG –0.9 –17.6 8.4** 6.5 16.0 6.0
Non-HDL –1.3* –1.7* –0.9** 12.8 15.5 9.8
Minor hypoglycemia events 
(events/patient year)
3.79*  4.8  2.6  0.27  0.4  0.1 
*p  0.05 repaglinide/metformin FDC monotherapy compared with rosiglitazone/metformin FDC monotherapy; **p  0.05 repaglinide/metformin FDC dual therapy compared 
with rosiglitazone/metformin FDC dual therapy.
Abbreviations: MT, monotherapy; DT, dual therapy; ∆, end of study change from baseline.Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2009:2 108
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Patient perspective
Although treatment with more than one oral agent is essential 
in the management pathway of type 2 diabetes, adherence 
is an issue, particularly with elderly patients. Patients with 
type 2 diabetes who have switched to other FDCs (of gliben-
clamide and metformin) are more likely to comply with their 
therapy.13,14,42 This suggests that compliance is also likely 
to improve in patients taking repaglinide/metformin FDC 
compared with separate doses of each tablet. The combina-
tion of the two treatments may allow patients who experience 
side effects with metformin to reduce the dose of metformin 
without a loss of glycemic control.
Conclusion
Repaglinide, a rapid-acting insulin secretagogue, targets PPG, 
and metformin, an insulin sensitizer, targets FBG, the two 
key determinants of overall hyperglycemia. Repaglinide and 
metformin are frequently co-administered as separate formula-
tions to manage hyperglycemia in patients with type 2 diabetes. 
Given that the effects of the two molecules are complementary 
and they may even act synergistically, the provision of both 
in a FDC is a logical step. The repaglinide/metformin FDC is 
effective in reducing HbA1c and in achieving HbA1c targets, 
whether it is taken twice or three times daily, meaning that 
patients can take fewer tablets less frequently than with dual 
therapy with individual tablets, thus reducing the risk of 
nonadherence associated with multiple tablets.
There is an increased drive in diabetes management 
towards early combination oral therapy to treat patients 
with type 2 diabetes to target to reduce the risk of vascular 
complications. As well as reducing HbA1c to target, which 
has been shown to reduce the risk of these complications, 
repaglinide/metformin FDC, unlike the combination of rosi-
glitazone and metformin, improves the lipid profile, poten-
tially further reducing patients cardiovascular risk profile.
With the increasing numbers of people with type 2 
diabetes worldwide, and the need to manage this condition and 
its vascular complications effectively, repaglinide/metformin 
FDC provides physicians with an additional treatment option 
that reduces hyperglycemia with a good safety and tolerability 
profile, and the potential to improve adherence to therapy.
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